Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00229138 · ClinicalTrials.gov registry record · Phase 4

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients

A Phase 4 study, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 4
Development phase
291
Enrollment target

NCT00229138: Completed Phase 4 study, sponsored by Novartis Pharmaceuticals.

NCT00229138 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 291 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00229138, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 4
Development phase
291 participants
Enrollment target

Study Summary

This study will investigate the safety, tolerability and efficacy of EC-MPS with tacrolimus at both reference and reduced levels. This study will take into account safety aspects such as decreased renal toxicity by reducing the overall exposure to tacrolimus.

Interventions

  • DRUG EC-MPS, Tacrolimus

Trial Details

FieldValue
Enrollment Target 291 participants
Start Date 2005-09
Est. Completion 2007-03
Phase Phase 4
Novartis Pharmaceuticals

1,375 total trials

What the finished NCT00229138 record still lists

NCT00229138 is an interventional study that assigns participants to a tested intervention. The registered 291 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (44% lower).

The record links to 0 conditions, and to 1 intervention - of which EC-MPS, Tacrolimus is the first listed.

NCT00229138 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00229138 about?

NCT00229138 is a clinical study titled "Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients". This study will investigate the safety, tolerability and efficacy of EC-MPS with tacrolimus at both reference and reduced levels. This study will take into account safety aspects such as decreased renal toxicity by reducing the overall exposure to tacrolimus.

What is the current status of trial NCT00229138?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 291 participants. The study started on 2005-09. Estimated completion is 2007-03.

What interventions are being tested in trial NCT00229138?

The interventions under investigation include: EC-MPS, Tacrolimus (DRUG).

Who is sponsoring clinical trial NCT00229138?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00229138's enrollment target sits among peer trials

291 297th of 2000 higher than 1,704 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02074839 · 291 participants · Phase 1

    Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

  • NCT03769766 · 291 participants · Phase 3

    Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance

  • NCT06563479 · 291 participants · Phase 3

    A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer

  • NCT04429542 · 292 participants · Phase 1

    Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00229138, the US trial registry maintained by the National Library of Medicine. NCT00229138 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.